The global genetic disorder drugs market is anticipated to grow at a considerable CAGR during the forecast years. The key companies operating in the industry are highly inclined towards the adoption of different growth strategies including capacity expansion, partnerships, mergers and acquisitions, geographical expansion, new product launch, and product innovation to remain competitive in the marketplace.
Browse the full report description of “Global Genetic Disorders Drug Market Size, Share and Trends Analysis Report, By Type (Single Gene Disorders, Chromosome Disorders, Multifactorial Disorders, and Others), By Application (Hospital and Clinics), Forecast (2022-2028)” at https://www.omrglobal.com/industry-reports/genetic-disorders-drug-market
For instance, the US Food and Medicine Administration (FDA) approved a new drug in August 2019 as the first ever treatment for a rare genetic metabolic disease that causes complete light sensitivity. The first medicine created by Australian biopharmaceutical company CLINUVEL, SCENESSE (afamelanotide 16mg), has been approved to "improve pain free light exposure in adult patients with a history of phototoxic responses from erythropoietic protoporphyria (EPP).
In August 2018, Galafold (migalastat), the first oral drug for the treatment of people with Fabry disease, was approved by the US Food and Drug Administration today. Adults with Fabry disease who have a genetic mutation that has been determined to be receptive ("amenable") to therapy with Galafold based on test evidence are eligible for the medicine. The buildup of a form of fat called globotriaosylceramide (GL-3) in blood arteries, kidneys, the heart, neurons, and other organs causes Fabry disease, a rare and dangerous hereditary condition. Fabry disease is an inherited condition caused by mutations (alterations) in the X-alpha-galactosidase chromosome's A (GLA) gene. Fabry disease is a rare genetic disorder that affects both men and women. Classic Fabry disease (the most severe kind) is thought to impact one out of every 40,000 males. The later-onset form is more common, with one in every 1,500 to 4,000 males in some communities. Slowly progressing renal disease, cardiac hypertrophy (heart enlargement), arrhythmias (abnormal heart rhythm), stroke, and early mortality are all symptoms of Fabry disease.
Market Coverage
• The market number available for – 2022-2028
• Base year- 2021
• Forecast period- 2022-2028
• Segment Covered-
o By Type
o By Application
• Regions Covered-
o North America
o Europe
o Asia-Pacific
o Rest of the World
• Competitive Landscape- AstraZeneca group Co., Eli Lilly and Co., F. Hoffmann-La Roche Ltd., Novartis International AG, Pfizer Inc., and Others.
Key questions addressed by the report
• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• How has COVID-19 impacted the market?
o Deviation from the pre-COVID-19 forecast
o Most affected region and segment
• Who is the leader in the market?
• How are players addressing challenges to sustain growth?
• Where is the investment opportunity?
Global Genetic Disorder Drugs Market Report Segment
By Type
By Application
Global Genetic Disorder Drugs Market Report Segment by Region
North America
• The US
• Canada
Europe
• UK
• Germany
• Italy
• Spain
• France
• Rest of Europe
Asia-Pacific
• China
• India
• Japan
• South Korea
• Rest of Asia-Pacific
Rest of the World
• Latin America
• Middle East & Africa
To learn more about this report request a free sample copy @ https://www.omrglobal.com/request-sample/genetic-disorders-drug-market